National Kidney Foundation

If you know someone living with immunoglobulin A nephropathy (IgAN), or Berger’s disease, this clinical research study may be an option. Learn more: bit.ly/4oN0ojP

This clinical research study is evaluating an investigational treatment option to potentially help manage and slow the progression of immunoglobulin A nephropathy (IgAN), or Berger’s disease. Learn more: bit.ly/4oN0ojP

Patients living with Immunoglobulin A nephropathy (IgAN), or Berger’s disease, may be eligible for a clinical research study that may help improve kidney function and slow the progression of IgAN. Learn more: bit.ly/3H23xMj

Join us virtually as we highlight real-world implementation data from NKF’s flagship CKDintercept program, a national strategy to improve CKD testing, diagnosis, and management in the primary care setting. RSVP: bit.ly/4niApQz

Today is #C3GAwarenessDay! C3G is a rare kidney disease with a lifelong impact. Explore our resources for understanding, diagnosing, and treating C3G. kidney.org/kidney-topics/…

Patients with kidney disease deserve more than outdated technology and limited options. Let’s create better treatments and better outcomes. support.kidney.org/campaign/69947…

We are one community united by a shared belief in the lifesaving power of our collective steps. Will you contribute to our goal by walking with us? KidneyWalk.org #KidneyWalk

Jessika and Joey didn’t let kidney failure stop them from falling in love or planning a wedding at the Kidney Walk. Here’s how their NKF community helped make it happen. kidney.org/news-stories/h…

TODAY is Kidney Heroes Giving Day! Today we honor KIDNEY HEROES and the life-changing difference they make for people with kidney disease. From donors and recipients to doctors and family members, anyone can be a kidney hero. Honor your hero: bit.ly/44W83Wq

When Patrick experienced sudden foot pain, he never imagined it would lead to a diagnosis of IgA nephropathy, or IgAN, a serious form of chronic kidney disease. kidney.org/news-stories/1…

Currently, there aren’t enough donated kidneys to meet the growing demand. But xenotransplantation could help change that. kidney.org/news-stories/c…

If you know someone living with immunoglobulin A nephropathy (IgAN), or Berger’s disease, this clinical research study may be an option. Learn more: bit.ly/3H23xMj

Tell your legislator to support programs that work to increase early detection, improve outcomes, address health disparities, and develop innovative treatments for kidney patients. bit.ly/4bP557V

This clinical research study is evaluating an investigational treatment option to potentially help manage and slow the progression of immunoglobulin A nephropathy (IgAN), or Berger’s disease. Learn more: bit.ly/3H23xMj

RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of an investigational cell therapy, CABA-201, in patients with active lupus nephritis (LN) or active lupus (SLE) without renal involvement. Learn more about the study at reset-sle-trial.com.

The RAINIER Study aims to reach higher summits in IgAN research. Learn more: bit.ly/4kffEF2

Today is #KidneyCancerAwarenessDay! Do you know the facts about kidney cancer? Watch our short animated videos to learn more. bit.ly/3j1YGgr

Today is #FSGS Awareness Day! The New Era Act helps patients with rare kidney diseases by promoting early detection of rare and genetic kidney diseases, enhancing education of doctors and patients, and conducting more research. We need YOUR voice to push it across the finish line. bit.ly/3TdcYvh

Patients living with Immunoglobulin A nephropathy (IgAN), or Berger’s disease, may be eligible for a clinical research study that may help improve kidney function and slow the progression of IgAN. Learn more: bit.ly/3H23xMj

RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of an investigational cell therapy, CABA-201, in patients with active lupus nephritis (LN) or active lupus (SLE) without renal involvement. Learn more about the study at reset-sle-trial.com.